Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0901 vs Investigator's Choice in 2L+ Advanced/Metastatic Gastric or GEJ Adenocarcinoma (CLARITY Gastric 01)
NCT06346392Phase 3Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2024
- Primary completion
- May 2026
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 19
01
Overview
A Phase 3 trial of sonesitatug vedotin in gastric cancer (GC), gastroesophageal junction cancer, sponsored by AstraZeneca. Started Mar 2024; status: active, not recruiting.
02
Drugs
sonesitatug vedotin
03
Conditions
gastric cancer (GC)gastroesophageal junction cancer
Beyond the preview
Go deeper on NCT06346392.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06346392.